Resources » Technical Resource Centers » Antibody Drug Discovery Technical Resource » Antibody Drug Discovery Overview
Antibody Drug Discovery Process
The overall discovery process for Ab therapeutics can be broadly divided into five stages:
Often time, screening, hit generation & lead selection are also collectively referred to as "Lead Discovery". Activities leading up to the selection of the clinical candidate are referred to as "preclinical" work/research. While the language and choice of words changes from one publication to another, the concept remains the same.
Figure 1: Overview of discovery process for therapeutic antibodies leading to the selection of a clinical candidate is shown in the workflow above. Key activities at each of the five stages are listed in the text boxes.
The answer is that it depends on the target. Small molecules penetrate the cell whereas large molecules (Ab therapeutics) typically target cell surface molecules like receptors or tumor antigens. And hence research will dictate what kind of intervention is required in a particular disease pathway. See major differences between small molecule and large molecule research in the table below.
Table 1: Small molecule drugs vs large molecule drugs.
Small Molecule Drugs | Large Molecule Drugs |
---|---|
Differences | |
![]() |
Large ![]() |
Organic or metallic compounds that can bind proteins inside the body thereby altering their function in diseases |
Biological molecules (proteins,
monoclonal antibodies, vaccines etc.) |
Produced using synthetic chemistry |
Usually produced using recombinant DNA technology inside living cells |
Small size <1,000 Daltons |
Large size ~150,000 Daltons |
Work inside the cell |
Bind cell surface receptors |
Less specific |
Highly specific |
Easier to deliver [often oral] |
Delivery is difficult [usually thorough injection] |
Relatively cheaper to manufacture |
Manufacturing expensive |
Easier to replicate [generics] |
Difficult to replicate [biosimilars] |
Example: Aspirin |
Example: Somatropin, hGH, mAb |
The previous section in this series is "Antibody Formats". To review, Click Here.
GenScript’s Antibody Engineering group can build antibody library with up to 1010 individual clones, to speed up your antibody discovery efforts.
GenScript’s advanced Antibody Sequencing technology offers fast and professional sequencing services for your monoclonal antibodies.
GenScript has developed several cell-based ADCC/CDC functional assays to profile the efficacy and potency of your therapeutic antibodies using proprietary recombinant effector cells.
GenScript scientists’ extensive experience in antibody engineering can provide superior services such as antibody humanization, affinity maturation and more.
With solid expertise in recombinant antibody (rAb) production techniques, GenScript provides a comprehensive rAb service portfolio that deliver microgram to gram quantities of pure rAb for each stage of your Ab drug discovery program.
GenScript offers over 120 tumor and inflammation models for evaluation of in vivo efficacy, PK/PD, biomarker and bioanalysis studies. GenScript Anti-idiotype Antibody services are also a powerful tool for antibody drug PK/PD and immunogenicity studies.
You can also view our Recombinant Antibody Service Selection Guide to identify services that are the best match for your application.
Our customer service repsentatives are available 24 hours a day, Monday through Friday, to assist you.